Who owns AbCellera Biologics Inc. (ABCL)? Elite investor 13F holders
3 tracked elite investors reported holding AbCellera Biologics Inc as of 2026-06-30, including Tudor Investment, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | Abcellera Biologics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 16196049.00 USD | 2063191.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | Abcellera Biologics Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 7778793.00 USD | 990929.000000 | Shares | reduce | Original filing |
| D.E. Shaw | Abcellera Biologics Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 356633.00 USD | 45431.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.